8 results on '"Ertenli, Ali İhsan"'
Search Results
2. Methodology of a new inflammatory arthritis registry: TReasure
- Author
-
Tufan, Muge Aydin, Kalyoncu, Umut, Tascilar, Etem Koray, Ertenli, Ali Ihsan, Dalkilic, Huseyin Ediz, Bes, Cemal, Kucuksahin, Orhan, Kasifoglu, Timucin, Alpay Kanitez, Nilufer, Emmungil, Hakan, Kimyon, Gezmis, Yasar Bilge, Nafize Sule, Akar, Servet, Atagunduz, Mehmet Pamir, Koca, Suleyman Serdar, Ates, Askin, Yazisiz, Veli, Terzioglu, Ender, Ersozlu, Emine Duygu, Cinar, Muhammet, Mercan, Ridvan, Sahin, Ali, Erten, Sukran, Pehlivan, Yavuz, Yilmaz, Sedat, Kelesoglu Dincer, Ayse Bahar, Gercik, Onay, Coskun, Belkis Nihan, Yagiz, Burcu, Kaymaz Tahra, Sema, Aksoy, Aysun, Karadag, Omer, Kilic, Levent, Kiraz, Sedat, [Kalyoncu, Umut -- Ertenli, Ali Ihsan -- Karadag, Omer -- Kilic, Levent -- Kiraz, Sedat] Hacettepe Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Tascilar, Etem Koray] Okmeydani Training & Res Hosp, Rheumatol Clin, Istanbul, Turkey -- [Dalkilic, Huseyin Ediz -- Pehlivan, Yavuz -- Coskun, Belkis Nihan -- Yagiz, Burcu] Uludag Univ, Fac Med, Dept Internal Med, Div Rheumatol, Bursa, Turkey -- [Bes, Cemal -- Alpay Kanitez, Nilufer] Rheumatol Clin, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Istanbul, Turkey -- [Kucuksahin, Orhan] Istinye Univ, Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey -- [Kasifoglu, Timucin -- Yasar Bilge, Nazife Sule] Eskisehir Osmangazi Univ, Fac Med, Dept Internal Med, Div Rheumatol, Eskisehir, Turkey -- [Emmungil, Hakan] Trakya Univ, Fac Med, Dept Internal Med, Div Rheumatol, Edirne, Turkey -- [Kimyon, Gezmis] Mustafa Kemal Univ, Fac Med, Dept Internal Med, Div Rheumatol, Antakya, Turkey -- [Akar, Servet -- Gercik, Onay] Izmir Katip Celebi Univ, Fac Med, Dept Internal Med, Div Rheumatol, Izmir, Turkey -- [Atagunduz, Mehmet Pamir -- Kaymaz Tahra, Sema -- Aksoy, Aysun] Marmara Univ, Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey -- [Koca, Suleyman Serdar] Firat Univ, Fac Med, Dept Internal Med, Div Rheumatol, Elazig, Turkey -- [Ates, Askin] Ankara Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Yazisiz, Veli -- Terzioglu, Ender] Akdeniz Univ, Fac Med, Dept Internal Med, Div Rheumatol, Antalya, Turkey -- [Ersozlu, Emine Duygu] Adana Numune Training & Res Hosp, Unit Rheumatol, Adana, Turkey -- [Tufan, Muge Aydin] Baskent Univ, Unit Rheumatol, Adana Hosp, Adana, Turkey -- [Cinar, Muhammet -- Yilmaz, Sedat] Univ Hlth Sci, Gulhane Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Mercan, Ridvan] Namik Kemal Univ, Fac Med, Dept Internal Med, Div Rheumatol, Tekirdag, Turkey -- [Sahin, Ali] Cumhuriyet Univ, Fac Med, Dept Internal Med, Div Rheumatol, Sivas, Turkey -- [Erten, SUkran] Yildirim Beyazit Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey, TASCILAR, Koray -- 0000-0002-8109-826X, Kaymaz-Tahra, Sema -- 0000-0001-5706-4943, Kalyoncu, Umut, Tascilar, Etem Koray, Ertenli, Ali Ihsan, Dalkilic, Huseyin Ediz, Bes, Cemal, Kucuksahin, Orhan, Kasifoglu, Timucin, Alpay Kanitez, Nilufer, Emmungil, Hakan, Kimyon, Gezmis, Yasar Bilge, Nazife Sule, Akar, Servet, Atagunduz, Mehmet Pamir, Koca, Suleyman Serdar, Ates, Askin, Yazisiz, Veli, Terzioglu, Ender, Ersozlu, Emine Duygu, Tufan, Muge Aydin, Cinar, Muhammet, Mercan, Ridvan, Sahin, Ali, Erten, SUkran, Pehlivan, Yavuz, Yilmaz, Sedat, Kelesoglu Dincer, Ayse Bahar, Gercik, Onay, Coskun, Belkis Nihan, Yagiz, Burcu, Kaymaz Tahra, Sema, Aksoy, Aysun, Karadag, Omer, Kilic, Levent, Kiraz, Sedat, İç Hastalıkları, İstinye Üniversitesi, Hastane, and Ege Üniversitesi
- Subjects
Male ,0301 basic medicine ,Turkey ,Cross-sectional study ,Inflammatory arthritis ,NECROSIS FACTOR THERAPY ,Datasets as Topic ,Biologics Register ,CLINICAL HISTORY ,registry ,DISEASE-ACTIVITY ,Arthritis, Rheumatoid ,Unique identifier ,0302 clinical medicine ,Disease-Activity ,Psoriatic-Arthritis ,Health care ,disease-modifying antirheumatic drugs ,Necrosis Factor Therapy ,Prospective Studies ,Registries ,Cerrahi ,Rheumatoid-Arthritis ,Clinical History ,ANKYLOSING-SPONDYLITIS ,General Medicine ,Middle Aged ,spondyloarthritis ,BACK-PAIN ,Antirheumatic Agents ,Cohort ,Society Classification Criteria ,Female ,Back-Pain ,Treasure ,medicine.medical_specialty ,TReasure ,Drug Industry ,DIAGNOSTIC-CRITERIA ,Ankylosing-Spondylitis ,03 medical and health sciences ,Spondylarthritis ,medicine ,Humans ,Rheumatoid arthritis ,Diagnostic-Criteria ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,medicine.disease ,RHEUMATOID-ARTHRITIS ,Cross-Sectional Studies ,030104 developmental biology ,Rheumatoid arthritis,spondyloarthritis,disease-modifying antirheumatic drugs,registry,TReasure ,Family medicine ,PSORIATIC-ARTHRITIS ,BIOLOGICS REGISTER ,030221 ophthalmology & optometry ,SOCIETY CLASSIFICATION CRITERIA ,Observational study ,Health Facilities ,Societies ,business - Abstract
WOS: 000441766000023, PubMed ID: 30119164, Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
- Published
- 2018
3. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic.
- Author
-
KALYONCU, Umut, PEHLİVAN, Yavuz, AKAR, Servet, KAŞİFOĞLU, Timuçin, KİMYON, Gezmiş, KARADAĞ, Ömer, DALKILIÇ, Ediz, ERTENLİ, Ali İhsan, KILIÇ, Levent, ERSÖZLÜ, Duygu, BES, Cemal, EMMUNGİL, Hakan, MERCAN, Rıdvan, EDİBOĞLU, Elif Durak, KANITEZ, Nilüfer, BİLGİN, Emre, ÇOLAK, Seda, KOCA, Süleyman Serdar, GÖNÜLLÜ, Emel, and KÜÇÜKŞAHİN, Orhan
- Subjects
COVID-19 pandemic ,RITUXIMAB ,PANDEMICS ,COVID-19 ,PATIENT compliance ,ARTHRITIS ,TERMINATION of treatment ,VISUAL analog scale - Abstract
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience.
- Author
-
BİLGİN, Emre, CEYLAN, Furkan, DURAN, Emine, FARİSOĞULLARI, Bayram, BÖLEK, Ertuğrul Çağrı, YARDIMCI, Gözde Kübra, KILIÇ, Levent, AKDOĞAN, Ali, KARADAĞ, Ömer, BİLGEN, Şule Apraş, KİRAZ, Sedat, ERTENLİ, Ali İhsan, and KALYONCU, Umut
- Subjects
PROPORTIONAL hazards models ,DRUG efficacy ,HERPES zoster ,LOGISTIC regression analysis - Abstract
Background/aim: To assess the real-life efficacy, retention rate, and safety data of tofacitinib in rheumatoid arthritis (RA) patients. Materials and methods: We analyzed all patients registered in the HURBİO database who received at least 1 dose of tofacitinib. Patients who received at least one dose were included in retention analysis; patients with at least 1 control visit were included in efficacy and safety analysis. Factors predicting good response at the last follow-up visit were analyzed by logistic regression analysis. Drug retention rates were calculated using the Kaplan--Meier method and predictors of drug retention were determined by Cox proportional hazard model. Adverse events, reasons for switching, and discontinuation were also determined. Results: Two hundred and forty-seven (210, 85.0% female) patients were included in the study. The median duration of tofacitinib treatment was 10.2 (20.2) [med, (IQR)] months. Two hundred and four (82.6%) patients were included in safety and efficacy analysis; 45.6% of patients were in low-disease activity (LDA) state (DAS28-CRP ≤ 3.2). Predictors of LDA were being biologic-naïve [aOR 2.53 (1.31--4.88); 95% CI] and RF negativity [aOR 2.14 (1.12--4.07); 95% CI]. At 1 year, the overall tofacitinib retention rate was 63.9% with no relevant predicting factor. Response and retention rates of tofacitinib were similar in patients with and without concomitant csDMARDs. Treatment failure was the most common cause of discontinuation. The most common infectious and laboratory adverse events were herpes zoster infection (3.9 per 100 patient-years) and elevation in ALT (x3UNL: 9.7 per 100 patient-years), respectively. Conclusion: Tofacitinib is effective as monotherapy or in combination with csDMARDs. It is a well-tolerated treatment option in Turkish RA patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Romatoid artrit ve spondiloartritte biyolojik DMARD'lar arasında geçiş ve nedenleri: TReasure gerçek yaşam verileri.
- Author
-
Kalyoncu, Umut, Ertenli, Ali İhsan, Kücükşahin, Orhan, Dalkılıç, Hüseyin Ediz, Erden, Abdulsamet, Bes, Cemal, Kanıtez, Nilüfer Alpay, Kaşifoğlu, Timuçin, Kızılırmak, Pınar, Emmungil, Hakan, Coşkun, Belkis Nihan, Yağız, Burcu, Koca, Süleyman Serdar, Çınar, Muhammet, Ateş, Aşkın, Akar, Servet, Ersözlü, Duygu, Yazısız, Veli, Bilge, Nazife Şule Yaşar, and Kimyon, Gezmiş
- Subjects
- *
DRUG side effects , *PATIENT compliance , *RHEUMATOID arthritis , *BIOCHEMICAL mechanism of action , *FOLLOW-up studies (Medicine) - Abstract
Objective: To determine features of patients switching between biological (b) DMARDs in rheumatoid arthritis (RA) and spondyloarthritis (SpA) treatments and to investigate associated reasons. Methods: This multicenter, prospective, observational cohort study used the TReasure database in which web-based registration of RA and SpA patients are being performed in 15 centers across Turkey. In this study, switching rates between bDMARDs, associated reasons, and features were analyzed in patients continuing bDMARD treatments during their follow-up periods. Results: Analysis included 2115 RA patients and 3138 SpA patients, of whom 829 (39.2%) RA and 1165 (37.1%) SpA patients switched to another bDMARD and 1286 (60.8%) RA and 1973 (62.9%) SpA patients continued to receive their current therapies (continued group). Median follow-up duration was 3.7 (range: 0-58.4) years in RA patients and 3.8 (range: 0-45.1) years in SpA patients. Female proportion was higher in both RA and SpA patients in the switched group. The first bDMARD used was an anti-TNF in 60.9% of RA patients and another bDMARD in 39.1%. According to switching patterns between bDMARDs, of RA patients, 41% switched from one anti-TNF to another and 38.4% switched from one anti-TNF to a bDMARD with other mechanism of action. The main reasons for switching in both RA and SpA patients were primary or secondary ineffectiveness and side effects. Conclusion: Further data on compliance to bDMARD treatment and treatment discontinuation or switching from one bDMARD to another in rheumatologic patients are needed to improve outcomes of patients and to ensure rational use of health expenditures. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey.
- Author
-
KAYA, Filiz, İNKAYA, Ahmet Çağkan, ERTENLİ, Ali İhsan, ABBASOĞLU, Osman, AKSOY, Sercan, AKYÖN YILMAZ, Yakut, and ERGÜVEN, Sibel
- Subjects
IMMUNOCOMPROMISED patients ,ANKYLOSING spondylitis ,RHEUMATOID arthritis ,NEMATODES as carriers of disease ,STRONGYLOIDIASIS - Abstract
Background/aim: In immunosuppressed patients, strongyloidiasis can be lifethreatening because of hyperinfection or dissemination. Therefore, diagnosis of S. stercoralis is important in immunosuppressed patients with chronic strongyloidiasis. In this study, our objective was to investigate the presence of S. stercoralis antibodies by an ELISA method in immunosuppressed patients. Materials and methods: A total of 100 immunosuppressed patients' sera were included in the study. Forty-two of the patients were receiving immunosuppressive therapies for cancer or being treated for hematopoietic malignancies, 38 of the patients were receiving immunosuppressive drugs for rheumatic diseases, 14 were receiving immunosuppressive therapies for liver transplantation. Two of the patients were being treated for HIV infection and 4 were being treated for hypogammaglobulinemia. As control group, 50 individuals without a known disease were included in the study. The presence of IgG antibodies against S. stercoralis was investigated with a commercial ELISA kit. Results: S. stercoralis antibody test was positive in 4 of 100 (4%) sera from immunosuppressed patients. All control patients were negative for S. stercoralis. Conclusion: Strongyloidiasis can be a lifelong chronic infection if not treated. In patients who are going to receive immunosuppressive therapy, it should be tested before treatment, as it can become a disseminated and life-threatening infectious disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Methodology of a new inflammatory arthritis registry: TReasure.
- Author
-
KALYONCU, Umut, TAŞCILAR, Etem Koray, ERTENLİ, Ali İhsan, DALKILIÇ, Hüseyin Ediz, BES, Cemal, KÜÇÜKŞAHİN, Orhan, KAŞİFOĞLU, Timuçin, ALPAY KANITEZ, Nilüfer, EMMUNGİL, Hakan, KİMYON, Gezmis, YAŞAR BİLGE, Nazife Şule, AKAR, Servet, ATAGÜNDÜZ, Mehmet Pamir, KOCA, Süleyman Serdar, ATEŞ, Aşkın, YAZISIZ, Veli, TERZİOĞLU, Ender, ERSÖZLÜ, Emine Duygu, TUFAN, Müge Aydın, and ÇINAR, Muhammet
- Subjects
ARTHRITIS patients ,RHEUMATOLOGY ,COHORT analysis ,DATA entry ,ANTIRHEUMATIC agents - Abstract
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
- Author
-
Orhan Küçükşahin, Servet Akar, Emel Gönüllü, Duygu Ersözlü, Sedat Kiraz, Gezmiş Kimyon, Hakan Emmungil, Umut Kalyoncu, Ali İhsan Ertenli, Nihan Coşkun, Emre Bilgin, Rıdvan Mercan, Yavuz Pehlivan, Omer Karadag, Hüseyin Dalkiliç, Cemal Bes, Süleyman Serdar Koca, Burcu Yağız, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Seda Colak, Elif Durak Ediboglu, Levent Kilic, İç Hastalıkları, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut, Pehlivan, Yavuz, Akar, Servet, Kaşifoğlu, Timuçin, Kimyon, Gezmiş, Karadağ, Ömer, Dalkılıç, Ediz, Ertenli, Ali İhsan, Kılıç, Levent, Ersözlü, Duygu, Beş, Cemal, Emmungil, Hakan, Mercan, Rıdvan, Ediboğlu, Elif Durak, Bilgin, Emre, Çolak, Seda, Koca, Süleyman Serdar, Gönüllü, Emel, Küçükşahin, Orhan, Coşkun, Nihan, Yağız, Burcu, Kiraz, Sedat, Koç University Hospital, and School of Medicine
- Subjects
rheumatoid arthritis ,Male ,Bath ankylosing spondylitis disease activity index ,Inflammatory arthritis ,polymerase chain reaction ,very elderly ,health status ,Disease ,Arthritis, Rheumatoid ,Cohort Studies ,rituximab ,adalimumab ,Pandemic ,middle aged ,disease modifying antirheumatic drug ,Health Assessment Questionnaire ,Prospective Studies ,Registries ,golimumab ,Aged, 80 and over ,register ,Ankylosing Spondylitis Disease Activity Score ,secukinumab ,adult ,medication compliance ,Simplified Disease Activity Index ,Biologic DMARDs ,General Medicine ,spondyloarthritis ,Middle Aged ,cohort analysis ,aged ,female ,spondylarthritis ,Rheumatoid arthritis ,drug withdrawal ,Antirheumatic Agents ,young adult ,Rituximab ,Female ,biologic DMARDs ,medicine.drug ,prospective study ,Adult ,medicine.medical_specialty ,abatacept ,hydroxychloroquine ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Visual analogue scale ,COVID-19 ,Spondyloarthritis ,salazosulfapyridine ,methotrexate ,Article ,Medication Adherence ,tocilizumab ,coronavirus disease 2019 ,Young Adult ,remission ,Internal medicine ,medicine ,DAS28 ,Humans ,human ,Pandemics ,Aged ,leflunomide ,business.industry ,SARS-CoV-2 ,pandemic ,questionnaire ,General and internal medicine ,visual analog scale ,medicine.disease ,major clinical study ,Discontinuation ,certolizumab pegol ,Bath ankylosing spondylitis functional index ,antirheumatic agent ,observational study ,erythrocyte sedimentation rate ,business ,infliximab ,Crohn Disease Activity Index ,etanercept ,disease activity - Abstract
Background/aim: to evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: a total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: a total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored., Hacettepe Rheumatology Society
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.